Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Age ≥ 18 years, all genders, and ethnic origins
Free, informed, and written consent signed
Person affiliated to or benefiting from a social security scheme
Age < 18 years
Lack of informed consent
Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)
Persons under administrative or judicial protection
Sequential
FA ablation
Procedure/SurgeryAblation of the FA
Lab test
Biological/VaccineBlood collection
Biomarkers T1
The individuation of biomarkers uniquely present in AF patients - compared to control groups.
Biomarkers T2
The individuation of biomarkers uniquely present in AF patients - compared to control groups.
Biomarkers 2
The identification of biomarkers predictive of the risk of AF recurrence
Algorithm
Identification of the machine learning algorithm with the best predictive performance for AF recurrence
Atrial electroanatomy and apneas
Existence of correlation between atrial electroanatomy and apneas accompanied by desaturation
Click on the lead sponsor to view all of their trials.
